[go: up one dir, main page]

ES2421587T3 - Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica - Google Patents

Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica

Info

Publication number
ES2421587T3
ES2421587T3 ES06751956T ES06751956T ES2421587T3 ES 2421587 T3 ES2421587 T3 ES 2421587T3 ES 06751956 T ES06751956 T ES 06751956T ES 06751956 T ES06751956 T ES 06751956T ES 2421587 T3 ES2421587 T3 ES 2421587T3
Authority
ES
Spain
Prior art keywords
treatment
systemic mastocytosis
pyrimidylaminobenzamide derivatives
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06751956T
Other languages
English (en)
Inventor
Leila Alland
Doriano Fabbro
Jürgen Mestan
Paul W Manley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Application granted granted Critical
Publication of ES2421587T3 publication Critical patent/ES2421587T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-N-[5-(4-metil-1H-imidazol-1-il)-3-(trifluorometil)fenil]-benzamida de fórmula (ll):**Fórmula** o un N-óxido o sales farmacéuticamente aceptables del mismo, para la fabricación de un medicamento para el tratamiento o la prevención de mastocitosis sistémicaagresiva, en el que dicha mastocitosis sistémica agresiva tiene resistencia al tratamiento de imatinib.
ES06751956T 2005-05-02 2006-05-01 Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica Active ES2421587T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67674005P 2005-05-02 2005-05-02
PCT/US2006/016541 WO2006119154A1 (en) 2005-05-02 2006-05-01 Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis

Publications (1)

Publication Number Publication Date
ES2421587T3 true ES2421587T3 (es) 2013-09-04

Family

ID=36867557

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06751956T Active ES2421587T3 (es) 2005-05-02 2006-05-01 Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica

Country Status (14)

Country Link
US (2) US20080176879A1 (es)
EP (1) EP1879585B1 (es)
JP (1) JP5129123B2 (es)
KR (1) KR101376875B1 (es)
CN (2) CN101171013A (es)
AU (1) AU2006242311B2 (es)
BR (1) BRPI0609296A2 (es)
CA (1) CA2606716C (es)
ES (1) ES2421587T3 (es)
MX (1) MX2007013741A (es)
PL (1) PL1879585T3 (es)
PT (1) PT1879585E (es)
RU (1) RU2445960C2 (es)
WO (1) WO2006119154A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004020654D1 (de) 2003-11-18 2009-05-28 Novartis Ag Hemmer der mutanten form von kit
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
JO3634B1 (ar) * 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
US10087129B2 (en) 2014-12-26 2018-10-02 Kao Corporation Method for producing cyclic diketone compound
EP3512515A1 (en) * 2016-09-16 2019-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
KR102535842B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 비만세포증 예방, 개선 또는 치료 용도

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
HUT74464A (en) * 1993-10-12 1996-12-30 Du Pont Merck Pharma 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO1998055152A1 (en) 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AU8477998A (en) 1997-11-13 1999-06-07 Histatek, Llc Small peptides and methods for treatment of asthma and inflammation
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
US20040157855A1 (en) 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
JP2005503361A (ja) * 2001-06-29 2005-02-03 アブ サイエンス 肥満細胞症治療のための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) * 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
CN1625602A (zh) 2002-03-13 2005-06-08 霍夫曼-拉罗奇有限公司 选择药物敏感性决定因子的方法和利用所选择的因子预测药物敏感性的方法
JP2005508846A (ja) * 2002-04-05 2005-04-07 ノバルティス　アクチエンゲゼルシャフト アレルギー性疾患のような肥満細胞系疾患に対するｎ−フェニル−２−ピリミジンアミン誘導体の使用
JP4032140B2 (ja) * 2002-07-02 2008-01-16 大原商事株式會社 つけ爪の取り付け方法
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
AU2004273605B2 (en) 2003-09-19 2008-07-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
DE602004020654D1 (de) 2003-11-18 2009-05-28 Novartis Ag Hemmer der mutanten form von kit

Also Published As

Publication number Publication date
AU2006242311A1 (en) 2006-11-09
US20080176879A1 (en) 2008-07-24
KR20080004563A (ko) 2008-01-09
CA2606716A1 (en) 2006-11-09
CN103638028A (zh) 2014-03-19
PL1879585T3 (pl) 2013-08-30
RU2007144530A (ru) 2009-06-10
EP1879585B1 (en) 2013-04-17
US8673930B2 (en) 2014-03-18
EP1879585A1 (en) 2008-01-23
CA2606716C (en) 2013-07-23
CN101171013A (zh) 2008-04-30
PT1879585E (pt) 2013-07-23
JP5129123B2 (ja) 2013-01-23
WO2006119154A1 (en) 2006-11-09
JP2008540420A (ja) 2008-11-20
KR101376875B1 (ko) 2014-03-27
US20100210673A1 (en) 2010-08-19
MX2007013741A (es) 2008-01-21
AU2006242311B2 (en) 2010-03-04
RU2445960C2 (ru) 2012-03-27
BRPI0609296A2 (pt) 2010-03-23

Similar Documents

Publication Publication Date Title
GEP20125691B (en) Compounds and compositions as protein kinase inhibitors
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
CO6450624A2 (es) Compuestos vinil indazolilo
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
MX394928B (es) Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
CL2013000884A1 (es) El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer.
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
NZ590839A (en) Treatment of pulmonary arterial hypertension
WO2007116025A3 (en) Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
JP2016020375A5 (es)
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
JP2012528824A5 (es)
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
ATE485280T1 (de) Pyrimidylderivate als proteinkinaseinhibitoren
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti
JP2008542390A5 (es)
BRPI0410704A (pt) uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete
WO2006012958A3 (en) Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
NO20072501L (no) Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMS
BRPI0818065A8 (pt) Quimioterapêutco derivado de indazol cristalino
TH148311A (th) การปลดปล่อยที่ถูกดัดแปรของ 4-เมธิล-3-[[4-(3-ไพริดินิล)-2-ไพริมิดินิล]อะมิโน]-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟูลออโรเมธิล)ฟีนิล] เบนซาไมด์ที่สามารถละลายได้โดยใช้กรดอินทรีย์
TH155598A (th) ไอโซซาโซลีน (Isoxazolines) ในฐานะเป็นตัวกระทำทางการรักษา ISOXAZOLINES AS THERAPEUTIC AGENTS
TH152470A (th) สูตรตำรับ 4-เมธิล-3-[[4-(3-ไพริดินิล-2-ไพริมิดินิลอะมิโน1-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟลูออโรเมธิล)ฟีนิล] เบนซาไมด์ชนิดปลดปล่อยทันที